Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia

Figures & data

Table 1. Demographics and therapies for included patients.

Patient ID	Age at diagnosis (years)	Received HU	Received IFN	TKI 1	Duration on TKI 1 (days)	TKI 2	Duration on TKI 2 (days)	Reason for switch**	TKI 3	Duration on TKI 3 (days)	Reason for switch**	Total duration on TKI (days)*
1	39	Y	Y	IM	6037	NA			NA			6037
2	37	N	N	BOS	1386	NA			NA			1386
3	23	N	N	IM	705	NIL	490	Failure	NA			1195
4	45	Y	N	IM	5707	NA			NA			5707
5	27	N	N	IM	1872	NA			NA			1872
6	37	Y	N	IM	251	DAS	31	Failure	NIL	2546	Intolerance	2825
7	37	N	N	IM	1350	NA			NA			1350
8	31	Y	Y	IM	944	NIL	926	Intolerance	NA			1870
9	32	Y	N	NIL	3560	NA			NA			3560
10	34	Y	N	IM	182	NIL	373	Failure	DAS	1910	Failure	2465
11	29	Y	N	DAS	818	IM	110	Intolerance	NA			928

BOS: bosutinib; DAS: dasatinib; HU: hydroxycarbamide; IM: imatinib; IFN: interferon; N: no; NA: not applicable; NIL: nilotinib; Y: yes.

*Calculated as the time between the start of TKI therapy and the date of the repeat semen analysis (post TKI).

**Based on the ELN criteria [5].

Table 2. Initial and repeat semen analyses.

Patient ID	Initial/pre-TKI sample			Repeat/post-TKI sample				Time between samples (days)
	Sperm/ml (x10^6)	% Progressive motility	% Total motility	Sperm/ml (x10^6)	Morphology (% normal forms)	% Progressive motility	% Total motility
1	16	44	54	4.2	2	NA	NA	6113
2	166	94	97	182.8	5	64	71	1413
3	5	15	17	3.2	NA	26	32	1209
4	167	45	55	277.5	5	54	58	5785
5	32	46	50	19.5	3	63	71	1892
6	118	61	68	208.5	2	52	56	2093
7	10.4	12	16	12.1	2	28	37	1361
8	20.4	67	71	27.6	1	45	53	1891
9	145	58	73	48.1	10	48	55	3567
10	185.8	80	87	223.5	4	64	68	2023
11	17.7	34	45	44.6	4	37	47	936

NA: not available.

Morphology was not available for any of the initial samples.

Reference ranges (≥ 15 × 10⁶ sperm/ml; ≥ 32% progressive motility; ≥ 40% total motility; ≥ 4% normal forms) [6].

Values in red are below the reference range.

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2

 PubMed Web of Science ®Google Scholar

World Health Organization. WHO laboratory manual for the examination and processing of human semen (FIFTH EDITION). https://www.who.int/docs/default-source/reproductive-health/srhr-documents/infertility/examination-and-processing-of-human-semen-5ed-eng.pdf?sfvrsn=5227886e_2. Updated 2010. Accessed 4/25, 2021.

 Google Scholar